Ablynx and Algeta enter into collaboration to evaluate Thorium-277 conjugated to nanobodies
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.
Under the terms of the collaboration, Ablynx will provide access to novel Nanobodies against a specific, undisclosed target and Algeta will provide access to chelation and conjugation technologies, as well as to its alpha-emitter thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially with the option for extension thereafter. No further terms have been disclosed.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Is lunar dust harmful to humans? - Roche’s xCELLigence System used to investigate effects of lunar and Martian dust on mammalian skin
AstraZeneca acquires DSM Biologics manufacturing facility in Canada

Real-time observation of enzymatic processes on DNA - Insights into the molecular processes involved in the detection of DNA strand breaks

The Mozart effect myth: Listening to music does not help against epilepsy - In the past, Mozart’s music has been associated with numerous ostensibly positive effects on humans, animals, and even microorganisms
Test developed to detect early-stage diseases with naked eye - Prototype ultra sensitive disease sensor developed
Medicyte and PRIMACYT Receive Grant to Develop Human Liver Cells for Cell-based Therapies
Takeda and Galaxy Biotech Sign License Agreement for Galaxy's Investigational Antibodies for the Treatment of Cancer

High-resolution microscope built from LEGO and bits of phone - Research shows constructing microscope improves children’s understanding - enlightening, educational and fun

Green adhesives made from whey - New process for obtaining valuable ethyl acetate
The American Physiological Society - Bethesda, USA

ImevaX GmbH - München, Germany
